

**FOR IMMEDIATE RELEASE**

Company Name Kyowa Kirin Co., Ltd.  
Representative Masashi Miyamoto, President and CEO  
(Code No. 4151, Prime Market of TSE)  
Inquiries Satoko Yoshida, Director,  
Corporate Communications Department  
Media Contact: +81-3-5205-7205  
Investor Contact: +81-3-5205-7206

**Notice regarding Completion of Share Acquisition of Orchard  
Therapeutics plc**

**Tokyo, London and Boston, January 24, 2024** - As announced in the “Notice regarding Agreement to acquire Shares of UK biopharmaceutical company Orchard Therapeutics plc” on October 5, 2023, Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, “Kyowa Kirin”) has been proceeding with Scheme of Arrangement under the UK Companies Act 2006 to acquire 100% of the outstanding shares of Orchard Therapeutics plc (NASDAQ: ORTX, CEO: Bobby Gaspar, “Orchard”), to make it a subsidiary.

At a hearing held on January 22, 2024, the High Court of Justice of England and Wales sanctioned the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 providing for the proposed acquisition (the “Transaction”) of Orchard by Kyowa Kirin. Subject to receipt of customary closing deliverables, the scheme of arrangement became effective upon delivery of the High Court’s order which sanctioned the scheme of arrangement to the Registrar of Companies in England and Wales, the delivery occurred on January 24, 2024, and upon which the Transaction closed. Consequently, Orchard has become a wholly-owned subsidiary of Kyowa Kirin as of today.

Following completion of the share acquisition procedures, Orchard will be delisted from the NASDAQ.

The overview of the acquisition will be disclosed when it becomes clear. And the administrative and financial impact of this acquisition on Kyowa Kirin will be disclosed in conjunction with the 2023 earnings announcement on February 7.

End